

## Detection of peripheral sensory loss is not straightforward

Sir, Detection of clinically significant neuropathy is essential for good diabetes care. We read with interest the article by Devoy *et al* (*Practical Diabetes*, vol 9 (5), page 197) describing the standard approach to examination of the peripheral sensory nervous system. A number of points arise which may be of particular importance in the assessment of elderly diabetic patients, who suffer the majority of foot ulcers<sup>1,2</sup>. Firstly, although thorough examination may be desirable, it is impractical in the average diabetic clinic where it may be more appropriate to concentrate on the diagnosis and exclusion of significant sensory loss.

It has been shown on many occasions that abnormalities of peripheral nerve function, indistinguishable from those of neuropathies including diabetes mellitus, may be found in apparently healthy elderly people<sup>3</sup>. Perception of vibration is most commonly impaired in old age. The loss of vibration perception is also quantitatively greater than for the other sensory modalities such that the distinction between significant sensory loss and age related change is difficult. In contrast perception of pin prick and light touch appear to be relatively preserved in old people and are probably the best clinical indicators of significant sensory neuropathy<sup>4</sup>, hence the best 'screening' modalities.

The role of the Biothesiometer in the diagnosis and assessment of neuropathy in elderly individuals is questionable. Vibration perception threshold (VPT) increases with age and the 'normal' VPT for octogenarians approaches the upper end of the Biothesiometer scale<sup>5</sup>. We have also demonstrated that in elderly people the variability of this instrument (for both consecutive and sequential readings) is considerable<sup>6</sup>.

FIONA THOMSON

Senior Registrar

Ladywell Hospital, Salford

EWAN MASSON

Senior Registrar in Medicine

Walton Hospital, Liverpool

### REFERENCES

1. Thomson FJ, Veves A, Ashe H *et al*. A team approach to diabetic foot care — the Manchester experience. *The Foot* 1991; 2: 75–82
2. Masson EA, Angle S, Roseman P, Soper C, Wilson I, Cotton M, Boulton AJM. Diabetic foot ulcers — do patients know how to protect themselves? *Practical Diabetes* 1989; 6: 22–23
3. George J. The neurological examination of the elderly patient. In: Tallis R (Ed) *The clinical neurology of old age*. John Wiley & Sons Ltd, Oxford, 1989: 67–75
4. Thomson FJ. The Epidemiology and Diagnosis of Diabetic Foot Problems in Elderly People. MD Thesis 1992, University of Manchester.
5. Wiles PG, Pearce SM, Rice PJS, Mitchell JMO. Vibration perception threshold: influence of age, height, sex and smoking, and calculation of accurate centile values. *Diabetic Med* 1991; 8: 157–161
6. Thomson FJ, Masson EA, Boulton AJM. Quantitative vibration perception testing in the elderly — an assessment of variability. *Age & Ageing* 1992; 21: 171–174

## Reflex zone therapy in use

Sir, One case report never proves anything, and whilst the case report "Reflex Zone Therapy in Use" from S C Martin and D J B Thomas was interesting (*Practical Diabetes*, vol 9 (5), page 198), their last paragraph suggests that this one case proves that reflex zone therapy works. They also describe the neuropathy as intractable, yet only give a three month history. Dr Peter Watkins' follow-up study has quite clearly shown that acute onset diabetic pain for neuropathy is virtually always self-limiting. Why this is, is not entirely clear, but it certainly can explain with great ease the last sentence in the letter which reads "success with reflex zone therapy has not yet been explained in the context of Western scientific medicine".

Dr A C BURDEN

Consultant Physician and Hon. Senior Lecturer  
Leicester General Hospital

## Isophane insulin not Ultratard™

Sir, Dr Mansell's study comparing isophane insulin with crystalline insulin zinc suspension (*Practical Diabetes*, vol 9 (6), page 214) confirmed my own feeling that most patients prefer an isophane insulin to provide 'basal' insulin cover, rather than the longer-acting Ultratard. At least, I think it did, but I am confused! While the abstract, the results and the conclusions all state that most of the patients in the study preferred isophane insulin, the first paragraph of the discussion concludes with the words "Most patients expressed a preference for and wished to use Human Ultratard".

MARILYN GALLICHAN

Diabetic Liaison Nurse

Cornwall

*The author apologises for this mistake: the sentence should have read "Most patients expressed a preference for and wished to use Human Insulatard™ and not Human Ultratard™ at the end of the study". An erratum to this effect was published on page 31 of the January/February issue of the journal, vol 10 (1).*

Editor

## Difficulties in interpreting blood pressure readings

Sir, I am grateful to Dr K Shotliff for his letter regarding my article "Quality control of blood pressure readings performed by practice nurses". I entirely agree with him that size of cuff is an important consideration when measuring blood pressure and this aspect was discussed in the teaching video. It was difficult to gain useful information from the questionnaire, however, as when I first wrote the article it was by no means certain that using the available large cuffs on all types of electronic and random zero machines gave reliable results. As Dr Shotliff points out, just because a large cuff is available does not mean it is used.

Other aspects were also omitted from the paper (although again highlighted in the video): for instance, the support of the arm. This is a neglected area and difficult to assess in practice. For example, in *Practical Diabetes*, vol 8 (2), page 47 a nurse is depicted measuring blood pressure in an unsupported arm.

I hope that my article and Dr Shotliff's letter will highlight the difficulties in interpreting blood pressure reading unless quality assurance procedures exist.

MARY BURDEN

Diabetes Specialist Nurse

Leicester General Hospital

## ADVERTISEMENT CORRECTION

Servier Laboratories Ltd wishes to make it clear that in portraying the front cover of the HMSO publication "CM1986 — The Health of the Nation — a Strategy for Health in England" as an integral part of an advertisement for Adifax, the Company had no intention of implying any form of Government or other official endorsement of the product or the advertisement. Servier Laboratories Ltd regrets that such an implication may have been drawn. Servier Laboratories Ltd regrets any embarrassment that this has caused to the Secretary of State for Health and the Controller of HMSO.